Journal Article DZNE-2026-00587

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Serum neurofilaments for motoneuron and dementia diseases: a German multicenter cohort study.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2026
Steinkopff [Darmstadt]

Journal of neurology 273(6), 356 () [10.1007/s00415-026-13878-y]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: Serum neurofilament light and heavy chains (sNfL and sNfH) have been assessed as neuronal markers for amyotrophic lateral sclerosis (ALS) and dementias. Whereas sNfL has robust literature, systematic studies on sNfH are lacking. Here, we aimed to assess the diagnostic value of sNfH in comparison to sNfL in a broad range of neurodegenerative disorders.We measured with immunoassays sNfH and sNfL in patients recruited in the multicenter German Frontotemporal Lobar Degeneration (FTLD) Consortium (n = 340) and in a single-center German cohort (n = 290). We assessed the diagnostic accuracy of serum biomarkers for ALS and dementia subtypes and their relationship with cognitive impairment.sNfH and sNfL were significantly increased in ALS (n = 90) vs. controls (n = 109) and ALS mimics (n = 56, p < 0.001), with sNfL showing higher discriminative accuracy (AUC = 0.94-0.95) than sNfH (AUC = 0.87-0.88). sNfH/sNfL ratio did not improve the diagnostic performance. Both markers were elevated in patients with dementia (n = 289) vs. controls (p < 0.001). sNfL was higher in behavioral variant frontotemporal dementia (bvFTD), primary progressive aphasia (PPA) and Creutzfeldt-Jakob disease (CJD) than in Alzheimer's disease (AD), whereas sNfH was similar in AD, PPA and bvFTD. sNfL, but not sNfH, was correlated with cognitive impairment at baseline and cognitive decline at follow-up in AD and bvFTD.sNfH and sNfL are elevated in motoneuron and dementia disorders. sNfH showed good discriminative accuracy for ALS, which was slightly lower than that of sNfL. sNfL, but not sNfH, showed prognostic value for assessing cognitive decline in dementia.

Keyword(s): ALS ; Biomarkers ; Dementia ; Neurofilaments ; NfL

Classification:

Contributing Institute(s):
  1. Translational Mass Spectrometry and Biomarker Research (AG Öckl)
  2. Clinical Dementia Research (Rostock /Greifswald) (AG Teipel)
  3. Molecular biomarkers for predictive diagnostics of neurodegenerative diseases (AG Wiltfang)
  4. Patient Studies (Bonn) (Patient Studies (Bonn))
Research Program(s):
  1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Database coverage:
Medline ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DEAL Springer ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Institute Collections > BN DZNE > BN DZNE-Patient Studies (Bonn)
Document types > Articles > Journal Article
Institute Collections > GÖ DZNE > GÖ DZNE-AG Wiltfang
Institute Collections > ROS DZNE > ROS DZNE-AG Teipel
Institute Collections > UL DZNE > UL DZNE-AG Öckl
Documents in Process
Public records
In process

 Record created 2026-06-03, last modified 2026-06-03


Restricted:
Download fulltext PDF Download fulltext PDF (PDFA)
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)